{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:07:13Z","timestamp":1765278433799,"version":"3.46.0"},"reference-count":23,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000762","name":"Imperial College Healthcare NHS Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2023-0008_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This is the first UK trial of pressurised intraperitoneal aerosolised chemotherapy (PIPAC) for colorectal cancer peritoneal metastases. This trial aimed to assess the impact of PIPAC in combination with standard of care systemic treatment on: progression free survival (PFS); quality of life (QoL); and short-term complications. In addition, this trial set out to demonstrate that PIPAC can be performed safely in operating theatres within a National Health Service (NHS) setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2023-0008_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Single-centre clinical trial with prospective data collection for patients undergoing 8-weekly PIPAC with oxaliplatin at 92\u202fmg\/m\n                      <jats:sup>2<\/jats:sup>\n                      from January 2019 till January 2022. Progression free survival was assessed using peritoneal carcinomatosis index (PCI) by CT scans and laparoscopy. Quality of life was assessed by EORTC QLQ-C30 questionnaire. Adverse events were recorded using CTCAE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2023-0008_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five patients underwent a total of ten PIPAC administrations (median 2, range 1\u20134). Median PFS was 6.0\u00a0months. QoL was maintained across repeat PIPAC procedures but a decrease in social functioning and increased fatigue were evident. Three incidences of grade 3 adverse events occurred but PIPAC was well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2023-0008_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The presented data demonstrates that PIPAC is feasible and can be safely delivered within the NHS for patients with colorectal cancer peritoneal metastases, but caution must also be exercised given a risk of adverse events. Systemic chemotherapy can be safely administered at a different unit to the PIPAC procedure if both groups have clear lines of communication and timely data sharing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2023-0008","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T08:40:30Z","timestamp":1694162430000},"page":"157-165","source":"Crossref","is-referenced-by-count":7,"title":["UK trial of pressurised intraperitoneal aerosolised chemotherapy (PIPAC) with oxaliplatin for colorectal cancer peritoneal metastases (NCT03868228)"],"prefix":"10.1515","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6150-6625","authenticated-orcid":false,"given":"Peter","family":"Kyle","sequence":"first","affiliation":[{"name":"Department of Surgery and Cancer , Imperial College London , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kitrick","family":"Perry","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Moutadjer","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Gilfillan","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalind","family":"Webb","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolan","family":"Basak","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Ziprin","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer , Imperial College London , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Blunt","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Burn","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Van Ree","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Sergot","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Murphy","sequence":"additional","affiliation":[{"name":"Imperial College London , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"2025120909250747241_j_pp-2023-0008_ref_001","doi-asserted-by":"crossref","unstructured":"Franko, J, Shi, Q, Meyers, JP, Maughan, TS, Adams, RA, Seymour, MT, et al.. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol 2016;17:1709\u201319. https:\/\/doi.org\/10.1016\/s1470-2045(16)30500-9.","DOI":"10.1016\/S1470-2045(16)30500-9"},{"key":"2025120909250747241_j_pp-2023-0008_ref_002","doi-asserted-by":"crossref","unstructured":"Patel, CM, Sahdev, A, Reznek, RHCT. MRI and PET imaging in peritoneal malignancy. Cancer Imag 2011;11:123\u201339. https:\/\/doi.org\/10.1102\/1470-7330.2011.0016.","DOI":"10.1102\/1470-7330.2011.0016"},{"key":"2025120909250747241_j_pp-2023-0008_ref_003","doi-asserted-by":"crossref","unstructured":"Nadler, A, McCart, JA, Govindarajan, A. Peritoneal carcinomatosis from colon cancer: a systematic review of the data for cytoreduction and intraperitoneal chemotherapy. Clin Colon Rectal Surg 2015;28:234\u201346. https:\/\/doi.org\/10.1055\/s-0035-1564431.","DOI":"10.1055\/s-0035-1564431"},{"key":"2025120909250747241_j_pp-2023-0008_ref_004","doi-asserted-by":"crossref","unstructured":"Qu\u00e9net, F, Elias, D, Roca, L, Go\u00e9r\u00e9, D, Ghouti, L, Pocard, M, et al.. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021;22:256\u201366. https:\/\/doi.org\/10.1016\/s1470-2045(20)30599-4.","DOI":"10.1016\/S1470-2045(20)30599-4"},{"key":"2025120909250747241_j_pp-2023-0008_ref_005","doi-asserted-by":"crossref","unstructured":"Foster, JM, Sleightholm, R, Patel, A, Shostrom, V, Hall, B, Neilsen, B, et al.. Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology ProceduresOutcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherap. JAMA Netw Open 2019;2:e186847\u20137. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.6847.","DOI":"10.1001\/jamanetworkopen.2018.6847"},{"key":"2025120909250747241_j_pp-2023-0008_ref_006","doi-asserted-by":"crossref","unstructured":"Reymond, MA, Hu, B, Garcia, A, Reck, T, K\u00f6ckerling, F, Hess, J, et al.. Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator. Surg Endosc 2000;14:51. https:\/\/doi.org\/10.1007\/s004649900010.","DOI":"10.1007\/s004649900010"},{"key":"2025120909250747241_j_pp-2023-0008_ref_007","doi-asserted-by":"crossref","unstructured":"Solass, W, Kerb, R, M\u00fcrdter, T, Giger-Pabst, U, Strumberg, D, Tempfer, C, et al.. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 2014;21:553\u20139. https:\/\/doi.org\/10.1245\/s10434-013-3213-1.","DOI":"10.1245\/s10434-013-3213-1"},{"key":"2025120909250747241_j_pp-2023-0008_ref_008","doi-asserted-by":"crossref","unstructured":"Jacquet, P, Stuart, OA, Chang, D, Sugarbaker, PH. Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anti Cancer Drugs 1996;7:596\u2013603. https:\/\/doi.org\/10.1097\/00001813-199607000-00016.","DOI":"10.1097\/00001813-199607000-00016"},{"key":"2025120909250747241_j_pp-2023-0008_ref_009","doi-asserted-by":"crossref","unstructured":"Nadiradze, G, Horvath, P, Sautkin, Y, Archid, R, Weinreich, FJ, K\u00f6nigsrainer, A, et al.. Overcoming drug resistance by taking advantage of physical principles: pressurized intraperitoneal aerosol chemotherapy (PIPAC). Cancer 2020;12. https:\/\/doi.org\/10.3390\/cancers12010034.","DOI":"10.3390\/cancers12010034"},{"key":"2025120909250747241_j_pp-2023-0008_ref_010","doi-asserted-by":"crossref","unstructured":"Ploug, M, Graversen, M, Mortensen, MB. Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: a systematic review. Available from: https:\/\/doi.org\/10.1186\/s12885-020-6572-6.","DOI":"10.1186\/s12885-020-6572-6"},{"key":"2025120909250747241_j_pp-2023-0008_ref_011","doi-asserted-by":"crossref","unstructured":"Grass, F, Vuagniaux, A, Teixeira-Farinha, H, Lehmann, K, Demartines, N, H\u00fcbner, M, et al.. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. Br J Surg 2017;104:669\u201378. https:\/\/doi.org\/10.1002\/bjs.10521.","DOI":"10.1002\/bjs.10521"},{"key":"2025120909250747241_j_pp-2023-0008_ref_012","doi-asserted-by":"crossref","unstructured":"Taibi, A, Geyl, S, Salle, H, Salle, L, Mathonnet, M, Usseglio, J, et al.. Systematic review of patient reported outcomes (PROs) and quality of life measures after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Surg Oncol 2020;35:97\u2013105. https:\/\/doi.org\/10.1016\/j.suronc.2020.08.012.","DOI":"10.1016\/j.suronc.2020.08.012"},{"key":"2025120909250747241_j_pp-2023-0008_ref_013","doi-asserted-by":"crossref","unstructured":"Girardot-Miglierina, A, Clerc, D, Alyami, M, Villeneuve, L, Sgarbura, O, Reymond, MA, et al.. Consensus statement on safety measures for pressurized intraperitoneal aerosol chemotherapy. Pleura Peritoneum 2021;6:139\u201349. https:\/\/doi.org\/10.1515\/pp-2021-0125.","DOI":"10.1515\/pp-2021-0125"},{"key":"2025120909250747241_j_pp-2023-0008_ref_014","doi-asserted-by":"crossref","unstructured":"Lurvink, RJ, Rovers, KP, Nienhuijs, SW, Creemers, GJ, Burger, JWA, de Hingh, IHJ, et al.. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases-a systematic review. J Gastrointest Oncol 2021;12:S242-58. https:\/\/doi.org\/10.21037\/jgo-20-257.","DOI":"10.21037\/jgo-20-257"},{"key":"2025120909250747241_j_pp-2023-0008_ref_015","doi-asserted-by":"crossref","unstructured":"Jacquet, P, Sugarbaker, PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359\u201374. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23.","DOI":"10.1007\/978-1-4613-1247-5_23"},{"key":"2025120909250747241_j_pp-2023-0008_ref_016","doi-asserted-by":"crossref","unstructured":"Aaronson, NK, Ahmedzai, S, Bergman, B, Bullinger, M, Cull, A, Duez, NJ, et al.. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","DOI":"10.1093\/jnci\/85.5.365"},{"key":"2025120909250747241_j_pp-2023-0008_ref_017","doi-asserted-by":"crossref","unstructured":"Giger-Pabst, U, Tempfer, CB. How to perform safe and technically optimized pressurized intraperitoneal aerosol chemotherapy (PIPAC): experience after a consecutive series of 1200 procedures. J Gastrointest Surg 2018;22:2187\u201393. https:\/\/doi.org\/10.1007\/s11605-018-3916-5.","DOI":"10.1007\/s11605-018-3916-5"},{"key":"2025120909250747241_j_pp-2023-0008_ref_018","doi-asserted-by":"crossref","unstructured":"Balmer, A, Clerc, D, Toussaint, L, Sgarbura, O, Ta\u00efbi, A, H\u00fcbner, M, et al.. Selection criteria for pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatment in patients with peritoneal metastases. Cancer 2022;14:2557. https:\/\/doi.org\/10.3390\/cancers14102557.","DOI":"10.3390\/cancers14102557"},{"key":"2025120909250747241_j_pp-2023-0008_ref_019","doi-asserted-by":"crossref","unstructured":"Li, Z, Wong, LCK, Sultana, R, Lim, HJ, Tan, JWS, Tan, QX, et al.. A systematic review on quality of life (QoL) of patients with peritoneal metastasis (PM) who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura Peritoneum 2022;7:39\u201349. https:\/\/doi.org\/10.1515\/pp-2021-0154.","DOI":"10.1515\/pp-2021-0154"},{"key":"2025120909250747241_j_pp-2023-0008_ref_020","doi-asserted-by":"crossref","unstructured":"Lurvink, RJ, Rovers, KP, Nienhuijs, SW, Creemers, GJ, Burger, JWA, de Hingh, IHJ, et al.. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with\u00a0colorectal peritoneal metastases-a systematic review. J\u00a0Gastrointest Oncol 2021;12. Available from: https:\/\/doi.org\/10.21037\/jgo-20-257.","DOI":"10.21037\/jgo-20-257"},{"key":"2025120909250747241_j_pp-2023-0008_ref_021","doi-asserted-by":"crossref","unstructured":"Tempfer, C, Giger-Pabst, U, Hilal, Z, Dogan, A, Rezniczek, GA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer. Arch Gynecol Obstet 2018;298:243\u201357.","DOI":"10.1007\/s00404-018-4784-7"},{"key":"2025120909250747241_j_pp-2023-0008_ref_022","doi-asserted-by":"crossref","unstructured":"Ceelen, W, Levine, E. Intraperitoneal cancer therapy: principles and practice. Boca Raton, Florida: CRC Press; 2016. pp. 394\u20135. Available from: https:\/\/www.routledge.com\/Intraperitoneal-Cancer-Therapy-Principles-and-Practice\/Ceelen-Levine\/p\/book\/9780367575250.","DOI":"10.1201\/b19409"},{"key":"2025120909250747241_j_pp-2023-0008_ref_023","unstructured":"National Institute for Health and Clinical Excellence. Overview | Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis | Guidance | NICE [Internet]; 2020. Available from: https:\/\/www.nice.org.uk\/guidance\/ipg681."}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2023-0008\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2023-0008\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:02:44Z","timestamp":1765278164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2023-0008\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,9,11]]},"published-print":{"date-parts":[[2023,12,22]]}},"alternative-id":["10.1515\/pp-2023-0008"],"URL":"https:\/\/doi.org\/10.1515\/pp-2023-0008","relation":{},"ISSN":["2364-768X"],"issn-type":[{"type":"electronic","value":"2364-768X"}],"subject":[],"published":{"date-parts":[[2023,9,11]]}}}